By Deena Beasley and Julie Steenhuysen
June 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' GILD.O lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.
Gilead said the drug will be sold under the brand name Yeztugo.
(Reporting by Deena Beasley in Los Angeles and Julie Steenhuysen in Chicago; Editing by Bill Berkrot and Alan Barona)
((deena.beasley@thomsonreuters.com; 213 955 6746; Reuters Messaging: deena.beasley.thomsonreuters.com@reuters.net))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。